Table 5.
Effects of inhibitors treatment on the genes involved lipid biosynthesis and transportation
| Accession number | Putative production encoded by the gene | Fold changes in gene expression |
|---|---|---|
| Tebuconazole treatment | ||
| EIT74279.1 | Hypothetical protein with fatty acid elongase domain | − 4.1 |
| EIT77602.1 | Ergosterol biosynthesis ERG4/ERG24 family protein | − 3.0 |
| EIT74308.1 | Acetylcholinesterase/butyrylcholinesterase | − 2.8 |
| EIT81567.1 | Leucine rich repeat protein with phospholipid binding domain | − 2.8 |
| EIT75089.1 | Long chain fatty acyl-CoA synthetase | − 2.1 |
| EIT72491.1 | Delta(14)-sterol reductase (AoERG24-B) | 1.6 |
| EIT75885.1 | Putative dienelactone hydrolase | 1.9 |
| EIT79617.1 | Gluconate 5-dehydrogenase | 2.2 |
| EIT81441.1 | Fatty acid synthetase | 2.4 |
| EIT80791.1 | Esterase/lipase | 2.8 |
| EIT74373.1 | Carboxylesterase family protein | 3.8 |
| EIT77624.1 | Acyl-CoA synthetase | Inf |
| Terbinafine treatment | ||
| EIT80216.1 | Acyl-CoA synthetase | –Inf |
| CEJ94122.1 | Hypothetical protein with cytochrome P450 domain | − 5.1 |
| EIT76912.1 | Flavin oxidoreductase/12-oxophytodienoate reductase | − 4.8 |
| EIT78275.1 | Hypothetical protein which may involves in alcohol sensor | − 3.2 |
| EIT80997.1 | Acyl-CoA synthetases (AMP-forming)/AMP-acid ligases II | − 2.4 |
| EIT77697.1 | Lipase | − 2.4 |
| EIT76480.1 | Benzoate 4-monooxygenase cytochrome P450 | − 2.3 |
| EIT80068.1 | 1-acyldihydroxyacetone-phosphate reductase | − 2.3 |
| EIT80560.1 | 1-aminocyclopropane-1-carboxylate deaminase | − 1.9 |
| EIT75499.1 | C-4 methylsterol oxidase (AoERG25-B) | − 1.8 |
| EIT78007.1 | 3-hydroxyacyl-CoA dehydrogenase | 1.7 |
Inf means infinite and –inf means minus infinity